Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Title
Intervention Indication Therapeutic Area Year Actions
Pembrolizumab with Bacillus Calmette-Guerin for treating high-risk non-muscle invasive bladder cancer Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2023 View  |  Download
Pembrolizumab perioperative therapy with neoadjuvant chemotherapy for treating cisplatin eligible muscle-invasive bladder cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2022 View  |  Download
Pembrolizumab and chemoradiation for treating muscle-invasive, non-metastatic bladder cancer Chemoradiotherapy , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2023 View  |  Download
Oportuzumab monatox for non-muscle invasive bladder cancer - second line Oportuzumab monatox (Vicinium; VB4-845; Proxinium) Bladder cancer Urological Cancer 2020 View  |  Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Bladder cancer Oncology , Urological Cancer 2021 View  |  Download
Neoadjuvant nivolumab with gemcitabine and cisplatin followed by adjuvant nivolumab for previously-untreated muscle-invasive bladder cancer Cisplatin (Platinol) , Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Bladder cancer Urological Cancer 2023 View  |  Download
Enfortumab vedotin with pembrolizumab for treating bladder cancer Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2023 View  |  Download
Durvalumab with gemcitabine-cisplatin neoadjuvant treatment and durvalumab adjuvant treatment for muscle-invasive bladder cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2022 View  |  Download
Durvalumab with Bacillus Calmette-Guerin for treating non-muscle invasive bladder cancer Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2022 View  |  Download
Durvalumab in combination with Tremelimumab for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2017 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications